Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 12, 2007, Pages 2467-2475

  Poggi, M ^a,b   Paulmyer Lacroix, O ^a,b   Verdier, M ^a,b   Peiretti, F ^a,b   Bastelica, D ^a,b   Boucraut, J ^a,c   Lijnen, H R ^d   Juhan Vague, I ^a,b   Alessi, Marie Christine ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Acute infammation; LPS; Lymphocyte; Mice; PAI 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; ENDOTOXEMIA; FIBRIN DEPOSITION; GENE OVEREXPRESSION; INFLAMMATION; LEUKOCYTE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TRANSGENIC MOUSE; WILD TYPE;

EID: 36348984961     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02757.x     Document Type: Article

References (45)

1. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996; 97: 2440-51.
2. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86: 543-9.
3. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75: 902-7.
4. Matsuno N, Ikeda T, Ikeda K, Hama K, Iwamoto H, Uchiyama M, Kozaki K, Narumi Y, Kikuchi K, Degawa H, Nagao T. Changes of cytokines in direct endotoxin adsorption treatment on postoperative multiple organ failure. Ther Apher 2001; 5: 36-9.
5. Tani T, Hanasawa K, Kodama M, Imaizumi H, Yonekawa M, Saito M, Ikeda T, Yagi Y, Takayama K, Amano I, Shimaoka H, Ohta M, Okahisa T, Koga N, Fujita N, Yamasa H. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients. World J Surg 2001; 25: 660-8.
6. Montes R, Declerck PJ, Calvo A, Montes M, Hermida J, Munoz MC, Rocha E. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb Haemost 2000; 84: 65-70.
7. Yamamoto K, Shimokawa T, Yi H, Isobe K, Kojima T, Loskutoff DJ, Saito H. Aging accelerates endotoxin-induced thrombosis: Increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol 2002; 161: 1805-14.
8. Burysek L, Syrovets T, Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 2002; 277: 33509-17.
9. Syrovets T, Jendrach M, Rohwedder A, Schule A, Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood 2001; 97: 3941-50.
10. Syrovets T, Schule A, Jendrach M, Buchele B, Simmet T. Ciglitazone inhibits plasmin-induced proinflammatory monocyte activation via modulation of p38 MAP kinase activity. Thromb Haemost 2002; 88: 274-81.
11. Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, Peppelenbosch MP, van der Poll T. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003; 101: 4446-8.
12. Abraham E, Gyetko MR, Kuhn K, Arcaroli J, Strassheim D, Park JS, Shetty S, Idell S. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003; 170: 5644-51.
13. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 1996; 97: 1818-26.
14. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000; 165: 1513-9.
15. Vaughan DE. PAI-1 and cellular migration: Dabbling in paradox. Arterioscler Thromb Vasc Biol 2002; 22: 1522-3.
16. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100: 58-67.
17. Kirchheimer JC, Binder BR, Remold HG. Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue. J Immunol 1990; 145: 1518-22.
18. Marshall LJ, Ramdin LS, Brooks T, PC DP, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003; 171: 2057-65.
19. Nykjaer A, Moller B, Todd RF III, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 1994; 152: 505-16.
20. Jones-Carson J, Fantuzzi G, Siegmund B, Dinarello C, Tracey KJ, Wang H, Fang FC, Vazquez-Torres A. Suppressor alphabeta T lymphocytes control innate resistance to endotoxic shock. J Infect Dis 2005; 192: 1039-46.
21. Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, Kopp F, Collen D, Juhan-Vague I, Alessi MC. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
22. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-55.
23. Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-9.
24. Goldblum SE, Wu KM, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985; 59: 1978-85.
25. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003; 23: 1262-8.
26. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006; 16: 115-23.
27. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-7.
28. Gunji Y, Gorelik E. Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 1988; 48: 5216-21.
29. Reid GG, Newman I. Human leucocyte migration through collagen matrices containing other extracellular matrix components. Cell Biol Int Rep 1991; 15: 711-20.
30. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25: 450-5.
31. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383: 441-3.
32. Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, Makarova A, Hyman BT, Strickland DK, Zhang L. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006; 25: 1860-70.
33. Viswanathan K, Liu L, Vaziri S, Dai E, Richardson J, Togonu-Bickersteth B, Vatsya P, Christov A, Lucas AR. Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways. Thromb Haemost 2006; 95: 499-510.
34. Arndt PG, Young SK, Worthen GS. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway. J Immunol 2005; 175: 4049-59.
35. Renckens R, Roelofs JJ, Bonta PI, Florquin S, de Vries CJ, Levi MM, Carmeliet P, van 't Veer C, van der Poll T. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 2007; 109: 1593-601.
36. Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen HR, Carmeliet P, van der Poll T. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 2005; 3: 1018-25.
37. Sejima T, Madoiwa S, Mimuro J, Sugo T, Okada K, Ueshima S, Matsuo O, Ishida T, Ichimura K, Sakata Y. Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol 2005; 174: 8135-43.
38. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197: 403-11.
39. Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4+ CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003; 197: 111-9.
40. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
41. Thornton AM, Shevach EM. CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-96.
42. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
43. Piccirillo CA, Shevach EM. Cutting edge: Control of CD8+ T cell activation by CD4+ CD25+ immunoregulatory cells. J Immunol 2001; 167: 1137-40.
44. Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006; 118: 1-9.
45. Robertson AK, Hansson GK. T cells in atherogenesis: For better or for worse? Arterioscler Thromb Vasc Biol 2006; 26: 2421-32.